Start Up Costs Botox: A Phase 2b Double-Blind, Placebo-Controlled, Adaptive, Dose-Escalation Study to Evaluate the Safety and Efficacy of OnabotulinumtoxinA for the Achievement of Primary Fascial Closure Without the Use of Component

Grants and Contracts Details

StatusFinished
Effective start/end date12/28/23 → 3/27/24

Funding

  • AbbVie Incorporated: $10,768.00